When Should COVID Vaccines Get Full Approval? US FDA Squeezed By ‘Too Fast’ And ‘Too Slow’ Camps

Some experts argue full FDA approval will help boost vaccination rates that are waning, but others want the agency to mandate studies in special populations and gather other data before making a final decision.

Between a rock and a hard place
US FDA finds itself between a rock and hard place in the arguments for quick or slow approval of the mRNA COVID-19 vaccine BLAs. • Source: Alamy

More from Vaccines

More from Pink Sheet